Regeneron to Report Q4 Earnings: Is a Beat in the Cards?

Biotech giant Regeneron Pharmaceuticals, Inc. (REGN) is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025.The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $3.78 billion, while the same for earnings is pinned at$11.60 per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Dupixent Fuels Growth for REGNA significant chunk of Regeneron’s revenues comes from the sale of its lead drug, Eylea, which is approved for various ophthalmology indi ...